Performance snapshot
Apzumi is a specialized software development vendor with a strong concentration in healthcare and health-tech, supported by a large and consistent body of positive reviews spanning over six years. The overwhelming majority of ratings are perfect or near-perfect across all sub-metrics, with only one notable negative account citing cost and timeline overruns. Across the five evaluated categories, ratings skew Strong, anchored by multiple high-density reviews citing specific outcomes, named technologies, and project budgets. The single negative review introduces a mixed signal on reliability and delivery predictability that cannot be dismissed entirely.
Best for
Apzumi is best suited for healthcare and health-tech companies seeking a dedicated development partner for custom software, mobile apps, and web platforms. They demonstrate particular depth in medically regulated environments, IoT integration, and multi-platform mobile development.
Clients info
Apzumi's client base is heavily concentrated in healthcare, medical devices, and health-tech, with secondary representation in wellness, government, and software development. Clients range from early-stage startups and small businesses to mid-sized companies with up to 10,000 employees. Project budgets most commonly fall in the $10,000 to $199,999 range, with at least one engagement exceeding $200,000. Primary industries represented include Healthcare & Medical, Health-Tech & Digital Health, Wellness, Government & Nonprofit, Software Development. Typical client size bands include 1-10 Employees, 11-50 Employees, 51-200 Employees, 201-500 Employees. Common project budget ranges include Less than $10,000, $10,000 to $49,999, $50,000 to $199,999, $200,000 to $999,999.
Review strength
The assessment is based on 35 reviews across 2 platforms, with the primary body of evidence drawn from one verified professional review platform. The review base spans from 2019 to April 2026, making it current and substantive. Two reviews from a secondary platform dated 2017 carry negligible analytical weight due to age and lack of content depth. Review date range: January 2017 - April 2026.